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Abstract
Background: The steps of a high-throughput proteomics experiment include the separation, differential expression
and mass spectrometry-based identification of proteins. However, the last and more challenging step is inferring
the biological role of the identified proteins through their association with interaction networks, biological
pathways, analysis of the effect of post-translational modifications, and other protein-related information.
Results: In this paper, we present an integrative visualization methodology that allows combining experimentally
produced proteomic features with protein meta-features, typically coming from meta-analysis tools and databases,
in synthetic Proteomic Feature Maps. Using three proteomics analysis scenarios, we show that the proposed
visualization approach is effective in filtering, navigating and interacting with the proteomics data in order to
address visually challenging biological questions. The novelty of our approach lies in the ease of integration of any
user-defined proteomic features in easy-to-comprehend visual representations that resemble the familiar 2D-gel
images, and can be adapted to the user’s needs. The main capabilities of the developed VIP software, which
implements the presented visualization methodology, are also highlighted and discussed.
Conclusions: By using this visualization and the associated VIP software, researchers can explore a complex
heterogeneous proteomics dataset from different perspectives in order to address visually important biological
queries and formulate new hypotheses for further investigation. VIP is freely available at http://pelopas.uop.gr/
~egian/VIP/index.html.
Background
The objective of large-scale proteomics analyses is to
study the expression, function, modifications and inter-
actions of proteins, and thus provide answers to challen-
ging biological questions [1-4]. High-throughput
proteomics techniques include several experimental
steps (e.g., 2D Gel Electrophoresis-2DGE, Liquid Chro-
matography-LC, Mass Spectrometry-MS) that produce
large volumes of data [4-6]. Meta-analysis follows and
enriches the pool of proteomic features [7] with meta-
data, such as Gene Ontology (GO) annotation, informa-
tion about networks, pathways, and more. In biomarker
discovery studies in particular, it is necessary to inte-
grate experimental results with metadata coming from
various databases, pathway analysis software, and other
sources, in order to identify biologically relevant
biomarkers [8-13]. Information visualization techniques
have become a powerful tool for bioinformatics and sys-
tems biology applications, since they help address the
inherent difficulties in understanding large volumes of
heterogeneous data [14-16]. Visualization methods assist
in exploring the experimental results more efficiently
than by simply examining numbers in large-size tables
and lists [15,16], which lack the spatial organization and
conceal the relative quantification aspects that the
human eye can easily recognize. The necessity to man-
age diverse proteomics data and combine them in order
to facilitate the interpretation of the findings raises an
information visualization challenge: to produce clear and
meaningful visual representations that reinforce human
cognition and assist the user to gain understanding
about the underlying phenomena and causal relation-
ships suggested by the data [17]. The purpose of using
visualization in the proteomics context is to provide an
effective mechanism for establishing alternative informa-
tive views that can in turn provide biological insight,
while abstracting away the details of a large dataset that
could be overwhelming to the user.
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meta-features, along with features emanating from
experimental steps, can indicate a powerful mechanism
for addressing biological questions and formulating new
hypotheses in the context of proteomics analysis. The
presented visualizations are generated using the VIP
software [18], a user-friendly tool that allows the visual
integration and exploration of proteomics data and
metadata. Through representative scenarios we highlight
and discuss several functionalities of the VIP software
that allow the users to: (1) perform the desired graphical
encoding according to their needs, (2) control the para-
meters of the visualization, (3) interact with the visuali-
zation, and (4) expand the features workspace by
creating new features based on the combination of exist-
ing ones. In the following subsections we present and
discuss the limitations of several approaches related to
proteomics visualization, we provide examples of meta-
features, and describe how the proposed visualization
can assist in the interpretation of proteomics results.
Related work
In proteomics tools, we find several visualization
attempts for the differential display of proteomics data-
sets, the representation of LC/MS data sets as “virtual
gels”, and the annotation of 2D-gel spots. For example,
in Proteinscape the 2D gel spots are linked with their
identification data and annotated with a colored cross,
which is difficult to discern in a crowded 2D gel
image, according to the level of identification [19].
Delta2D is an image analysis software that stands out
for its impressive differential display based on the
spots intensity, and color-coding of the peaks, which
highlights proteins that are differentially expressed in
specific conditions [20,21]. Label color-coding is also
used to illustrate protein properties, such as pI and
MW, using continuous color gradients. However, add-
ing large color labels to an already busy 2D gel image
creates a visual result that is difficult to process.
Pep3D summarizes an LC-MS/MS dataset by placing
the peptide peaks in a 2D gel-like image, known as
“density plot”, using as coordinates the retention time
(RT) and mass-to-charge ratio [22]. In Pep3D, the
score values of peptide identification and the precursor
ions selected for fragmentation are depicted with
colored boxes around the peaks. However, Pep3D only
allows the visualization of a single experiment at a
time, and the boxes used to annotate the peaks are too
small to distinguish the color differences. Color has
also been used to display the ratio of differential
expression levels of identical peptides in two different
datasets, in 2D or 3D plots [23,24]. The height and
color of cones representing proteins have been used to
display up/down regulation [25].
Despite these attempts to visualize either 2DGE-MS or
LC-MS/MS data, these tools: (a) exploit either the size
or color of the glyph used to encode information and
create poor-in-information visual results, and (b) do not
allow the combined visualization of features coming
from different steps of a proteomics analysis. In the
meantime, the integration of any user-selected proteo-
mic features, including metadata, into interactive visual
representations, remains an open problem and poses
insightful challenges in bioinformatics research.
Definition of meta-features
The goal of proteomics is to “capture” the proteome at a
specific biological state and study the differential expres-
sion, functionality, interactions, and post-translational
modifications of the proteins. Thus, it is common prac-
tice for proteomics researchers to correlate the experi-
mental findings with knowledge gained from the
literature and data stored in frequently updated data-
bases, such as the protein type, biological process, loca-
tion in the cell, molecular pathways and more.
In particular, the protein types characterize groups of
proteins that have similar functionality (e.g., the
enzymes that catalyze chemical reactions). Protein func-
tionality refers to the activities (e.g., catalytic activity,
transporter activity, binding) that can be performed by
proteins. A series of such activities (i.e., functions) spe-
cify a biological process (e.g., biosynthetic process, signal
transduction, gluconeogenesis). Additionally, the protein
location (e.g., nucleus, cytoplasm, mitochondrion) is a
particular cellular compartment where the protein is
known to play its active role.
A protein network is a graph modelling protein inter-
actions: the nodes represent proteins and the edges
direct or indirect interactions between them [26]. Pro-
tein networks are widely used to summarize experimen-
tal results, to infer unknown functions of proteins and
to shed light on complicated molecular mechanisms. On
the other hand, biological pathways are subsets of net-
works containing proteins th a tc o m m u n i c a t eas i g n a l
from one part of the cell to another during a biological
process. Post-translational modifications (PTMs) are
chemical modifications that take place after the protein
translation [27,28]. In particular, PTMs can affect fold-
ing, increase or decrease protein activity, and alter pro-
tein functionality. Therefore it is likely that PTMs reveal
proteins related to observed phenotypical differences.
The identification of PTMs (e.g., phosphorylation, acety-
lation) is important because it can provide insight on
the function and role of proteins in biological systems.
Other meta-features can be considered as well, such as
protein-drug correlation, structural information, litera-
ture references and others, that might indicate even
more motivating questions.
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In previous work, we have introduced Proteomic Feature
Maps (PFMs) [7], a novel visualization approach that
represents proteomic objects (i.e., proteins or peptides)
as spheres, and encodes any two user-selected proteomic
features using its size and color. Two more features are
also encoded to the spheres (x, y)-coordinates on a map.
We have also developed VIP (Visualization for Inte-
grated Proteomics), a user-friendly software tool for the
visual exploration and analysis of heterogeneous proteo-
mics datasets based on the PFMs concept [18]. VIP (1)
integrates proteomic features, (2) combines them visually
to form PFMs and (3) offers several filtering, navigation
and interaction capabilities to the users. The flexibility
of the PFMs visualization methodology supported by
VIP allows creating PFMs using any desired proteomic
features, thus providing a mechanism for generating
easily different perspectives for a proteomics experi-
ment. More details on the software are provided in the
Methods section.
Meta-features in PFMs scenarios were not included in
our previous work [7]. However, it is a major task to be
considered since meta-features allow addressing challen-
ging biological questions, such as: “Are the identified
enzymes differentially expressed?“, “Which functions are
associated with the up regulated proteins?“, “Which pro-
teins, among the differentially expressed ones, have also
undergone post-translational modifications?”.I m p o r -
tantly, PFMs visualization is intentionally grounded on
two-dimensional maps that resemble 2D-gels, a familiar
data representation in proteomics, only now enriched
with color and size cues defined by the user. This simple
idea of augmenting existing representations [29,30]
makes the PFMs an intuitive and useful tool for proteo-
mics practitioners.
We demonstrate the effectiveness of the proposed
visualization methodology through three indicative pro-
teomics scenarios, where appropriately designed PFMs
are used to provide visual answers to important ques-
tions, meaningful in the context of proteomics data ana-
lysis and interpretation. For each presented scenario, we
demonstrate the use of the proposed visualization meth-
odology to generate visual summaries that can effec-
tively address these questions. In the discussion of each
scenario, we also highlight several interaction and navi-
gation functionalities of the software. Table 1 provides a
summary of the scenarios, the questions addressed and
the coded names of the corresponding PFMs. The pre-
sented examples aim at showing the flexibility of the
approach and the VIP software; other meta-features
could also be used to generate user-specific PFMs.
T h es c e n a r i o sw ec h o s et op r e s e n ts h o wt h a tV I Pc a n
be used to address effectively questions that biologists
commonly ask during a proteomics analysis. These real-
life questions, based on meta-features (e.g., protein type,
post-translational modifications, involvement in path-
ways and biological networks), were revealed from our
close interaction with a group of scientists in the Biome-
dical Research Foundation of the Academy of Athens
[29], who use proteomics routinely in order to elucidate
biological mechanisms.
By applying the PFMs visualization to real-life scenar-
ios we show that VIP users with minor effort can:
￿ Integrate visually disparate proteomic features origi-
nated from different databases and tools.
￿ Create multiple views for a proteomics experiment
in order to explore a dataset from alternative
perspectives.
￿ Query, navigate and interact with their visualizations,
in order to retrieve useful knowledge by recognizing
patterns and correlations.
￿ Skip the time-consuming task of working on long
protein lists when looking for biologically relevant rela-
tions suggested by their results.
Results and Discussion
In this section, we present three representative scenarios
that demonstrate the ways in which our visualization
methodology can be used to accelerate and enhance
proteomic analysis. Each scenario exercises a different
set of meta-features that can be visually combined and
integrated using the VIP software tool. Moreover, for
each scenario we discuss how VIP can help the users
interact with the visualization and address specific
questions.
Scenario 1 - Networks and Pathways Features
This scenario demonstrates how VIP contributes to data
interpretation by facilitating the association of proteo-
mics experimental results with information related to
biological networks and pathways.
As biology is transformed into an information-driven
integrative science, it becomes increasingly common,
captured during VIP requirements analysis, to correlate
experimental findings with known protein interaction
networks and pathways, in order to infer the underlying
biological mechanisms suggested by the data [8-13].
Moreover, in graphs and diagrams used to visualize
pathways and networks, it is typical to include informa-
tion regarding the protein differential expression (e.g.,
fold change), protein type, protein name, molecular
function and more.
We present below six typical questions, regarding the
involvement of proteins in biological networks and path-
ways, which will be addressed visually by the VIP tool
and the PFMs visualization.
Q1: Which are the up/down regulated proteins that
participate in the network “Cellular Assembly and
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Biochemistry"?
Q2: What are the molecular functions of the proteins
that belong to the network “Lipid Metabolism - Small
Molecule Biochemistry - Cell Cycle"?
Q3: What types of proteins (e.g., enzymes, transpor-
ters, cytokines) are involved in the network “Cell Mor-
phology - Cell Cycle - Inflammatory Response"?
Q4: What types of proteins appear in pathway “Glyco-
lysis/Gluconeogenesis"?
Q5: Which molecular functions/biological processes
are assigned to the proteins that belong to pathway
“Pentose Phosphate"?
Q6: Are there any common proteins in pathways “Fatty
Acid Metabolism” and “Glycolysis/Gluconeogenesis"?
In the next two subsections we detail two typical uses
of the PFMs visualization in this context. The corre-
sponding PFMs were based on the dataset generated
from a 2DGE-MS proteomics experiment (described in
Methods).
Network Map
In the PFM of Figure 1A (network map), we visualize
jointly the binary feature “protein belongs to network
Cellular Assembly and Organization, Neurological Dis-
ease, Small Molecule Biochemistry” and the volume fold
change feature, which shows the differential expression
(i.e., up/down regulation) of proteins (see Methods).
Specifically, in the PFM of Figure 1A, large spheres
represent proteins that participate in the network, while
red/green spheres are up/down regulated protein spots
(i.e., having log fold change value larger/smaller or equal
to 1/-1). Spots that had log fold change in the range
[-1,1] are depicted as blue spheres.
A brief examination of this PFM provides a visual
impression of the up/down regulated proteins of the
experiment that also participate in the specific network.
Moreover, the proteins that belong to the network but
were not differentially expressed are also easily visible as
large blue spheres. As a result, this network map sum-
marizes effectively the proteins of a dataset that belong
to an interaction network, in conjunction with their dif-
ferential expression information. The network map does
not aim at replacing network graphs, which demonstrate
the interactions of all proteins involved in a biological
network. Instead, the objective of this network map is to
visualize whether the proteins identified in a certain
experiment belong to a network of interest or not, while
preserving a visual reference to the familiar 2D gel
images of the experiment (Figure 1B). The PFM visuali-
zation also provides a clear, easy to grasp and interpret
image when compared to a manually annotated gel
image, which is usually crowded with spot ids and
accession numbers (Figure 1B). Such annotated gel
images, which are commonly found in published 2DGE-
based proteomics studies [11,30,31], tend to be cluttered
Table 1 Case studies summary
CASE STUDY 1 CASE STUDY 2 CASE STUDY 3
DESCRIPTION Involves the proteins participation in
interaction networks and pathways.
Combines the differentially expressed proteins
with basic meta-features (e.g., protein type,
protein location, mol. function)
Associates the proteins with
discovered post-translational
modifications (PTMs)
QUESTIONS
ADDRESSED
Q1: Which are the up/down regulated
proteins that participate in the network N?
Q1: Which proteins were found to be
differentially expressed based in both the X and Y
iTRAQ ratios?
Q1: Are the phosphorylated
proteins also differentially
expressed?
Q2: What are the molecular functions of the
proteins that belong to network N?
Q2: Are there any upregulated proteins found
only in the X or in the Y iTRAQ ratio?
Q2: Which proteins have
undergone phosphorylation?
Q3: What types of proteins (e.g., enzymes,
transporters) are involved in the network N?
Q3: What is the location of the differentially
expressed proteins?
Q3: What is the peptide sequence
that is “responsible” for a
phosphorylated protein?
Q4: What types of proteins appear in
pathway P?
Q4: What types of proteins (e.g., enzymes,
transporters) are up-regulated?
Q4: Do the proteins that have
undergone oxidation belong to
any network/pathway?
Q5: Which molecular functions/biological
processes are assigned to the proteins that
belong to pathway P?
Q5: What are the molecular functions/biological
processes associated with the up-regulated
proteins?
Q5: What is the function of the
proteins that have undergone
acetylation?
Q6: Are there any common proteins in
pathways P1 and P2?
PFMs
USED
Network Map PFM=[belongs to network N,
fold change]
Differential Expression Comparison Map PFM=
[iTRAQ ratios comparison state, iTRAQ differential
expression]
Phosphorylation Map PFM=[has
undergone phosphorylation, iTRAQ
ratio]
Pathway Map PFM=[belongs to pathway P,
protein type]
A summary of the scenarios presented and discussed in the paper: short description, real-life questions concerning each scenario and the corresponding PFMs.
The notation PFM = [feature1, feature2] is used to show quickly the two features that have been associated with the size and color of the spheres respectively.
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Page 4 of 13Figure 1 Network and pathway maps of a 2DGE-MS experiment. (A) In the network map of Scenario 1, large spheres indicate proteins that
belong to a specific network, whereas their color (red/green/blue) indicates proteins’ up/down/no regulation. (B) A 2D gel image annotated
with the accession numbers of selected identified proteins. Such images, very often found in proteomics publications, are difficult for the user to
explore and need effort to indicate the interesting proteins/spots. The maps presented in Scenario 1 use the detected spots of this 2D gel. (C)
The result of a right click action on a specific sphere is a pop-up menu that contains user-selected information. In this case, the menu shows the
Object ID, Accession Number, Protein Name, Protein Type and Biological Process of a protein. (D) The user can select any one of the available
features to appear in the pop up menus of the spheres. (E) In the pathway map of Scenario 1, large spheres indicate proteins that belong to a
specific pathway, whereas their color (red/green/blue) indicates their protein type (also shown in the color bar). The result of a click action on a
specific sphere is highlighted corresponding table row, which contains all the features of the clicked sphere/protein.
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Page 5 of 13with arrows, circles and underlined font to mark differ-
entially expressed spots, making it even trickier for the
reader to distinguish interesting information.
The interaction capabilities offered by VIP can be
exploited in order to address questions similar to those
described before. For example, clicking on the sphere
shows the Object ID of a protein (Figure 1C1), which
characterizes uniquely every proteomic object in the
VIP workspace and corresponds to the spot number of
the protein in the gel. Thus, the user can answer a ques-
tion similar to Q1: “SSP 3006 is a down regulated pro-
tein that participates in the network Cellular Assembly
and Organization, Neurological Disease, Small Molecule
Biochemistry”. To answer the same question in terms of
the accession number or the name of a protein, the user
simply has to include these features in the pop-up menu
of the sphere. It then becomes clear that the selected
green and large sphere, which corresponds to a down
regulated protein involved in the network, has been
identified by the accession number “P07309” and is
known as “Transthyretin precursor - Mus musculus
(Mouse)” (Figure 1C2).
Appending features to the pop-up menu of the
spheres (Figure 1D) is straightforward and allows hand-
ling even more questions, such as Q2 and Q3, which
involve the protein type and molecular function. Figure
1C3, shows that the selected down regulated protein
that belongs to the specific network acts as a “transpor-
ter” and is associated with the molecular function “hor-
mone activity”. This useful VIP attribute allows the user
to retrieve the desired information for the proteins,
while exploring the map.
By creating a network map using the VIP tool, the
users benefit from:
(a) The PFM visualization as a means to summarize
the proteins participation in an interaction network,
along with their up/down regulation information.
(b) The VIP feature to rapidly access specific feature
values, and create quick visual displays in order to
address network-related questions.
Pathway Map
In the PFM of Figure 1E (pathway map), we visualize
jointly the binary feature “protein belongs to the path-
way Glycolysis/Gluconeogenesis” and the protein type
(e.g., enzyme, transporter) (see Methods).
A quick examination of the pathway map reveals
proteins that belong to the pathway of interest among
the proteins identified by the analysis (large spheres),
as well as the different types of proteins found to par-
ticipate in the pathway (three different colors of the
large-size spheres: red, green and pink). The protein
type (question Q4) can be retrieved from the color of
the sphere, the pop-up menu, or the highlighted row
of the table that stores all features of the protein (Fig-
ure 1E). Using the table also gives the advantage to
inspect all features related to the selected protein-
sphere. For example, one can retrieve from the table
the molecular functions biological processes associated
with the proteins that belong to the pathway (question
Q5).
Furthermore, to deal with a question similar to Q6,
VIP offers the capability to produce new features based
on existing ones and expand the features workspace on
demand. For example, several “belongs to pathway” bin-
ary features (see Methods) can be added to produce a
new counter-type feature that records the number of
pathways an identified protein belongs to. This new fea-
ture could then be visualized on a new PFM in order to
distinguish proteins that are found uniquely in a specific
pathway from proteins that participate in several
pathways.
To summarize, a pathway map, constructed using the
VIP tool, can facilitate the interpretation of proteomics
analysis results by offering:
(a) The effortless discrimination of proteins that parti-
cipate in a pathway along with significant complemen-
tary relevant features, such as the protein type and
molecular function.
(b) The capability to create on demand new features
based on existing ones in order to expand the features
workspace and the perspectives under which a proteo-
mics experiment can be visually explored.
Scenario 2 - Differential Expression Features
This scenario shows how the proposed visualization
methodology and the functionality of the VIP software
can enhance the differential expression analysis part of a
proteomics workflow.
Importantly, quite often researchers want to associate
t h ed i f f e r e n t i a l l ye x p r e s s e dp r o t e i n so fap r o t e o m i c s
dataset with different protein-related meta-features.
Such features, obtained by the GO, the Ingenuity Path-
way Analysis or other sources, may include (but are not
limited to):
￿ Protein type (e.g., enzyme, kinase, transporter,
transcription regulator, peptidase)
￿ Protein location (e.g., cytoplasm, nucleus, extracel-
lular space, plasma membrane)
￿ Molecular function (e.g., actin binding, kinase
activity, protein binding)
￿ Biological Process (e.g., anti-apoptosis, cellular bio-
synthetic process, DNA replication)
We present below five representative proteomic ques-
tions relevant to this scenario that will be addressed
visually in the next subsection.
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Page 6 of 13Q1: Which proteins were found to be differentially
expressed based in both the 118/116 and 119/117
iTRAQ ratios?
Q2: Are there any up regulated proteins found only in
the 118/116 ratio or in the 119/117 iTRAQ ratio?
Q3: What is the cellular location of the differentially
expressed proteins?
Q4: What types of proteins are up regulated?
Q5: What are the molecular functions/biological pro-
cesses associated with the up regulated proteins?
The map described in the following paragraph was
based on a dataset from a LC-MS proteomics experi-
ment (see Methods).
Differential Expression Comparison Map
To create the differential expression comparison map
(Figure 2A), we defined the feature “iTRAQ ratios com-
parison state” (see Methods) that allows locating easily
the differentially expressed proteins in one or both
iTRAQ ratios. The ratios we used (i.e., 118/116 and
119/117) are important for the specific study since they
capture differences within the wild type and transgenic
mice respectively, when the mice are fed with normal
diet (i.e., numerator labels 118 and 119) or injected with
an anorectic toxin (i.e., denominator labels 116 and
117). Thus, each iTRAQ ratio is indicative of the differ-
ential expression between two biological states. The
“iTRAQ ratios comparison state” is used to indicate pro-
teins that fall in one of the three categories:
S0: not differentially expressed in any of the two
ratios.
S1: differentially expressed in one of the two ratios
only (i.e., either in wild type or in transgenic mice).
S2: differentially expressed in both ratios (i.e., in
both types of mice).
For simplicity, we will call the 118/116 and 119/117
iTRAQ ratios, as Ratio 1 and Ratio 2. A quick examina-
tion of the differential expression comparison map (Fig-
ure 2A) reveals the proteins that have been differentially
expressed in one or both iTRAQ pairs (i.e., medium and
large spheres respectively) (question Q1). Proteins with-
out significant change in their expression levels are
depicted as small spheres. It is important to note that
this map shows only a subset of the identified proteins
Figure 2 Differential expression and phosphorylation maps of a LC-MS/MS experiment. (A) The differential expression map of Scenario 2
shows a subset of proteins identified by the LC-MS/MS experiment. The size indicates if the proteins are uniquely (medium size) or commonly
differentially expressed (large size) in two pairs of biological states (i.e., in two iTRAQ ratios). The color indicates the type of differential
expression: red (green) for up (down) regulation in at least one ratio, yellow for up/down regulation in the two ratios, and blue for no
differential expression in any ratio. (A1) Zoomed area of the differential expression comparison map, showing the Biological Process associated
with each protein in the spheres labels. (B) The phosphorylation map of Scenario 3 shows all proteins identified by the LC-MS/MS experiment.
Large spheres indicate proteins that have undergone phosphorylation, whereas their color (red/green/blue) indicates their up/down/no
regulation based on an iTRAQ ratio. (B1) Pop up menu of a right clicked protein, showing its Accession Number, the Spectrum id and the
sequence of the corresponding phosphorylated peptide.
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Page 7 of 13(i.e., 77 out of 691 proteins), which were differentially
expressed at least in one of the iTRAQ ratios used. This
user requirement reflects the emphasis given on the
proteins expression in a differential proteomics study.
We also created the feature “iTRAQ differential
expression” (see Methods) in order to represent the
direction of differential expression (i.e., up or down reg-
ulation) in each one of the two ratios. For example, if a
protein is associated with the “up/down” value it means
that this protein was found to be up regulated in Ratio
1, and down regulated in Ratio 2. Similarly, the “down/
down” value indicates down regulation in both ratios,
while the “-/up” value suggests that the protein was up
regulated in Ratio 2 only. After taking into consideration
these user requirements, the following categories related
to this feature were formed:
C0: non differentially expressed proteins (blue), C1:
up regulated proteins, at least in one ratio (red),
C2: down regulated proteins, at least in one ratio
(green),
C3: up regulated proteins in one ratio and down
regulated proteins in the other (yellow).
Table 2 summarizes and explains the size and color
categories used for the spheres of this map. The com-
mon use of size and color to encode differential expres-
sion information, also known as redundant encoding
[32], was deliberately chosen in order to provide quick
and reliable perception of the important features of dif-
ferential expression. To answer a question similar to
Q2, the user has to simply observe the map and look
for the spheres that are of medium size (proteins
differentially expressed only in one ratio) and red (pro-
teins up regulated).
From our interaction with the research group that car-
ried out the experiment and produced the dataset, we
noticed that the users found it difficult to correlate the
two ratios, and to identify the proteins of interest by
looking into a large table (i.e., spreadsheet) with many
iTRAQ numbers. However, they responded very posi-
tively in the combined visualization of the iTRAQ ratios
and integrated it into their workflow because they were
able to locate without effort the proteins that are differ-
entially expressed in only one ratio, or in both ratios.
This map also offers visual connection of the differen-
tial expression proteins with important protein-related
meta-features, such as the protein location, protein type,
as well as GO classification. In particular, the user could
map the protein location (question Q3), protein type
(question Q4), molecular function or biological process
(question Q5) to the label of the spheres in order to get
immediate access to the values of these features. For
example, in Figure 2A1 each protein-sphere carries a
label that denotes its biological process obtained from
the GO.
To sum up, the differential expression comparison
map, created using the VIP tool, allows the user to:
(a) Find and represent visually the proteins that were
differentially expressed in one or more biological states
of interest.
(b) Have instant access to the values of a selected fea-
ture using the label of the spheres.
Scenario 3 - Post-translational Modification Features
In this scenario we demonstrate how the proposed
visualization methodology can assist the users explore
visually the post-translational modifications (PTMs) that
exist in a proteomics dataset.
The increasing importance of detecting protein modi-
fications when studying phenotypes [27,33-35], moti-
vated us to evaluate the usefulness of PMFs based
visualization in a study concerned with PTMs. PTMs
are known to alter the protein properties, such as their
molecular function, interactions with other proteins, and
participation in a biological pathway. The discovery of a
PTM also provides strong motivation to a biochemist to
look deeper into the protein sequence and identify the
modified peptide. Once the modified peptide is identi-
fied, one can search whether this modification is already
known, or it is a new one. If a known modification has
occurred, interesting assumptions can be made for the
function of the proteins and their possible role in cer-
tain pathways. If the detected modification is unknown,
then a new series of experiments can be designed in
order to study the importance and role of the PTM in
the function and activity of a protein.
Table 2 Size and Color categories in Differential
Expression Comparison map
SIZE CATEGORIES
COLOR
CATEGORIES
S0
(small)
S1
(medium)
S2
(large)
C0
(BLUE)
-/- NA NA
C1
(RED)
NA UP/-
-/UP
UP/UP
C2
(GREEN)
NA DOWN/-
-/DOWN
DOWN/
DOWN
C3
(YELLOW)
NA NA UP/
DOWN/
DOWN/
UP
The table summarizes the size and color categories used for the Differential
Expression Comparison map, as well as the values assigned to each category.
The X/Y annotation is used to indicate that X (Y) is the type of differential
expression in Ratio 1 (Ratio 2) respectively, whereas the dash indicates no
differential expression in the corresponding category (e.g., UP/- means up
regulation in Ratio 1 and no significant differential expression in Ratio 2). NA
denotes a not available combination of size and color.
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protein PTMs that can trigger the researcher to perform
further investigation on the modified proteins. The fol-
lowing subsection also describes how PFMs based visua-
lization and the VIP tool can help the user address
these questions.
Q1: Are the phosphorylated proteins also differentially
expressed?
Q2: Which proteins have undergone phosphorylation?
Q3: What is the peptide sequence that has undergone
phosphorylation?
Q4: Do the proteins that have undergone oxidation
belong to a specific network/pathway?
Q5: What is the function of the proteins that have
undergone acetylation?
The map described in this scenario was also based on
the LC-MS dataset (described in Methods).
Phosphorylation Map
For the phosphorylation map of Figure 2B, we used the
binary feature “protein has undergone phosphorylation”
and the 118/116 iTRAQ ratio, which shows the differen-
tial expression (i.e., up/down regulation) of proteins (see
Methods). The experimental indication about the phos-
phorylation of the proteins was based on the results of
the ProteinPilot software [36] used in this study. This
map shows all identified proteins of the experiment (i.e.,
691 proteins, as opposed to the map of Scenario 2) in
order to include not only all differentially expressed, but
also all phosphorylated proteins.
The phosphorylation map of Figure 2B visually con-
firms that apart from the differentially expressed pro-
teins, one should also put particular emphasis on the
identification of PTMs: from the proteins that have
undergone phosphorylation (i.e., large spheres), only two
have been differentially expressed (i.e., large and green
spheres) (question Q1). This finding shows that if the
researchers had restricted the analysis only to the up/
down-regulated proteins, they would have missed the
significant information that the post-translationally
modified proteins carry (i.e., large blue spheres).
This map offers an effective visual summary of the
phosphorylated proteins that have been detected within
the experiment. It also assists in identifying proteins
that have undergone a PTM by retrieving their acces-
sion numbers (question Q2). Moreover, if this informa-
tion is available and imported in the VIP workspace, the
user could also retrieve the sequence of the modified
peptide of a phosphorylated protein, as well as the pep-
tide spectrum id (Figure 2B1). Using the spectrum id,
further analysis can be performed, such as viewing the
mass spectra file in the corresponding software (e.g.,
ProteinPilot [36]), in order to verify the modified
peptide.
The user can also combine the information regarding
the phosphorylated proteins with pathway or network-
related meta-features, as well as the molecular function
to address questions similar to Q4 and Q5. Due to
space limitations we do not provide examples using
these features, but we believe that the examples pre-
sented so far have provided convincing evidence on the
flexible adaptation of PFMs based visualization to the
proteomics analysis specific objectives.
Using a phosphorylation map, or a map regarding any
PTM (e.g., oxidation, methylation etc.), the user can:
(a) Establish a quick visual summary of the proteins
that have undergone the specific PTM and retrieve their
accession number, sequence and spectrum of the modi-
fied peptide in order to perform further analysis.
(b) Combine easily the PTM-related information with
other important meta-features (e.g., molecular function,
interaction networks, pathways presence) to formulate
new hypotheses on the potential role of a protein in cer-
tain molecular mechanisms.
Conclusions
We have demonstrated through three proteomics sce-
narios, which were defined from different user require-
ments, that the joint visualization of features, typically
produced by a proteomics experiment, along with meta-
features, can indicate a powerful mechanism for addres-
sing biological questions and formulating new hypoth-
esis for further investigation.
Throughout the discussion we have pointed out some
of the most significant functionalities of the VIP software
that can provide effective and comprehensive exploration
of the PFMs. In particular, the users can with minor
effort: (1) perform the desired graphical encoding accord-
ing to their needs, (2) control the parameters of the
visualization, such as the values-to-colors association, (3)
interact with the PFMs in order to rapidly retrieve speci-
fic feature values of the displayed proteomic objects, and
(4) expand the features workspace by creating new fea-
tures by combining existing ones.
In summary, the PFMs visualization, offered by the
freely available and user-friendly VIP software, allows
the users in the field of proteomics to:
￿ Visually integrate unconnected proteomic features
coming from different meta-analysis sources (i.e., data-
bases and pathway/network analysis tools).
￿ Generate alternative views for a proteomics experi-
ment, in order to analyze and explore a heterogeneous
dataset from multiple perspectives according to their
needs and objectives.
￿ Query, navigate and interact with their data and the
produced visualizations in order to address visually the
biological questions raised in a proteomics analysis
context.
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Page 9 of 13￿ Avoid the time-consuming and error-prone task of
looking for correlations and interesting relations within
large tables of raw data.
Due to its data integrative nature, the described
approach and associated software tool have the potential
to address major challenges in proteomics data analysis
and the fast growing discipline of systems biology. For
example, the differential comparison of biological condi-
tions that is also supported by VIP (e.g., through the dif-
ferential display of multiple PFMs), as well as the
capability to simultaneously display and compare on a
map multiple features, can facilitate inspecting biological
system properties at a global scale. Although the metho-
dology has been developed for proteomics it can be
applied to any system with components that can be
modelled by a set of features.
The evaluation of the usability of the software is also
in progress, using a task-driven methodology targeted to
the needs of proteomics practitioners. This evaluation
will help us examine the users’ reactions to specific
tasks (e.g., the creation of new features), enhance the
proposed visualization methodology, and possibly
expand the functionality of the software. To the best of
our knowledge, VIP is currently the only software tool
available in the public domain that supports explora-
tion-by-visualization of large-scale heterogeneous pro-
teomics datasets combining data and meta-data.
Methods
Datasets
This section provides information on the datasets used
in the presented scenarios. Experimental details that are
irrelevant to the work described in the paper are not
provided.
The objective of the 2DGE-MS study (dataset used in
Scenario 1) is the identification of proteins involved in
the mechanisms that lead to the development of fatty
liver in mice. In this study, wild type and transgenic
mice were fed with high fat diet (i.e., an experimental
manipulation to induce obesity or even to unmask
related phenotypes in mice) or normal diet (disease and
control groups respectively) and resulted in 4 categories:
(1) Wild type with normal diet, (2) Wild type with high
fat diet, (3) Transgenic with normal diet and (4) Trans-
genic with high fat diet. Liver tissues from all experi-
mental groups were subjected to proteomics analysis
creating four 2DGE gels per category. Pairs of categories
were compared and in each comparison the subset of
matched spots that passed at least two of the three sta-
tistical tests used (i.e., t-test, Mann-Whitney, Partial
Least Squares) and also satisfied the volume 2-fold
change quantitative criterion were considered as differ-
entially expressed. The differentially expressed spots in
the diseased versus the healthy subjects were then
identified using peptide mass fingerprinting (PMF). The
PDQuest image analysis software [37] was used for spot
detection and matching and MASCOT identification
engine [38] for protein identification.
The LC-MS study (dataset used in Scenarios 2 and 3)
aimed at identifying the differentially expressed proteins
in a well-characterized mouse model of high fat diet
induced obesity, as well as in a model of lipopolysac-
charide (LPS) induced anorexia. In this study, both wild
t y p ea n dt r a n s g e n i cm i c ew e r ef e dw i t hh i g hf a td i e to r
normal diet, or were injected with an anorectic dose of
LPS. The quantitative LC-MS/MS based method used 8-
plex iTRAQ™ reagents and resulted in several cate-
gories designated with the 116, 117, 118, 119 and 121
reporter ions. Each category corresponds to a different
s t a t e( e . g . ,1 1 6 :T r a n s g e n i cm i c ew i t hn o r m a ld i e t ,1 1 7 :
Wild type with normal diet, 118: Transgenic mice with
LPS, 119: Wild type with LPS, 121: Wild type with high
fat diet). The reporter ions ratio (e.g., 118/116, 119/117)
is indicative of the differential expression between the
two biological states of interest. In Scenario 2, we used
two ratios to capture differences between the transgenic
mice with normal diet and LPS (118/116), and the wild
type mice with normal diet and LPS (119/117). Finally,
the proteins were identified using MS/MS and the Pro-
teinPilot software [36].
Meta-Features
For the studies already described, meta-analysis was per-
formed using the Ingenuity Pathway Analysis software
package [39], which provided us with the protein type
and location, a list of interaction networks and canonical
pathways and many more meta-features. We also
exploited the VIP capability to perform an online query
search to UniProt database [40] and retrieve for each
protein additional meta-features, such as the number of
amino acids (AA), the theoretical isoelectric point (pI)
and molecular weight (MW), the grand average hydro-
phobicity index (GRAVY), and the Gene Ontology
annotation, including the Biological Process (BP), Mole-
cular Function (MF) and Cellular Component (CC).
Thus, we created a large pool of meta-features, in a sim-
ple tab-delimited text format, so as to produce PFMs
that could cope with questions similar to those
described in Table 1. Moreover, we consider as meta-
features the post-translational modifications (PTMs) dis-
covered by advanced high-throughput proteomics tech-
nologies (i.e., tandem mass spectrometry-MS/MS),
because although they are obtained at the experimental
step of mass spectrometry, they can only be sufficiently
exploited at a later meta-analysis step in the workflow.
The features “belongs to network N” and “belongs to
pathway P” of Scenario 1 and the feature “has under-
gone phosphorylation” of Scenario 2 are called binary
Giannopoulou et al. BMC Bioinformatics 2011, 12:308
http://www.biomedcentral.com/1471-2105/12/308
Page 10 of 13because they can only have two different values, 1 (true)
or 0 (false). Thus, they indicate: (1) the presence or
absence of a protein in network N, or pathway P,
respectively, or (2) whether a protein has undergone
phosphorylation or not. The network/pathway-related
features have been created manually by processing the
network/pathway lists that the Ingenuity Pathway Analy-
sis software produced. Similarly, we created the PTM-
related feature, by processing the proteins list that was
exported from ProteinPilot™.
Finally, the feature “iTRAQ ratios comparison state”
used in Scenario 2 has been created using the VIP cap-
ability to compute new features, either by performing a
function rule, or by adding existing features (i.e., sum
rule). To produce this feature we followed the steps:
1. Create a temporary feature, based on the function
rule:
IF ((Ratio1 < 0.8) OR (Ratio1 >1.2))
temp_feature1 = 1
ELSE
temp_ feature1 = 0
This temporary feature assigns the value 1 to the pro-
teins that are either down (i.e., Ratio1<0.8) or up regu-
lated (i.e., Ratio1>1.2).
2. Similarly, produce another temporary feature, using
the same rule but for Ratio2.
3. Use the sum rule to add the values of the two tem-
porary features. The result is the feature “iTRAQ ratios
comparison state”, which has three distinct values: 0, 1
and 2, denoting the number of ratios that a protein was
found to be differentially expressed on.
Graphical encoding
We use the size of the spheres to visually encode the
binary features (i.e., 1/0 for true/false); small and large
spheres show easily the two different states of the fea-
ture. For example, large spheres indicate proteins that
participate in a network or a pathway (Scenario 1), or
proteins that were phosphorylated (Scenario 3). Small
spheres depict the rest of the proteins in the dataset
(Scenario 1), or proteins that were not phosphorylated
(Scenario 3).
On the other hand, color was exploited to encode fea-
tures with values in a discrete or continuous range. For
example, in the network map of Scenario 1 (Figure 1A)
we use color to represent the fold change feature in
order to preserve the familiar association of color with
differential expression (up regulation - red, down regula-
tion - green) adopted since the early microarray-based
genomic studies. In the pathway map of Scenario 1 (Fig-
ure 1E), we also used color to encode eight different
protein types. Since protein type is a categorical feature,
we first associated each protein type with a number (e.
g., transporter: 1, translation regulator: 2). We also
created a user-defined color map and assigned different
colors to the protein types, so as to distinguish easily
proteins of the same type (e.g., red: enzymes, orange:
transporters). The color and protein type association is
shown in the color bar of Figure 1E.
In Scenario 2, we encoded the three discrete values of
the “iTRAQ ratios comparison state” feature (0 for cate-
gory S0, 1 for category S1 and 2 for category S2) to size.
Thus, three easy-to-grasp size categories were shaped:
small, medium and large spheres respectively. For the
“iTRAQ differential expression” feature, we used 4 dif-
ferent colors to depict the four different categories: blue
for non-differentially expressed proteins, red for up-
regulated, green for down regulated, and yellow for pro-
teins up-regulated in one ratio and down-regulated in
the other.
In Scenario 3, we chose to encode the 118/116 iTRAQ
ratio to color, in order to visualize the up/down regu-
lated proteins as red/green spheres (i.e., having 118/116
ratio > 1.2 or < 0.8 respectively) and the proteins with
no significant differential expression change (i.e., 118/
116 ratio between 0.8 and 1.2) as blue spheres.
In general, for features with a small number of distinct
values (e.g., up to 5 values), size can be employed to
depict differences. In contrast, color is well suited to be
used for features with a larger number of values, or
categorical features. Additionally, color can also be a
suitable encoding choice for continuous values (e.g., by
changing the lightness of a color), or for distinguishing
conditions (e.g., up regulation - red, down regulation -
green).
Proteomic Feature Maps and the VIP software
PFMs based visualization is a simple and powerful
approach, applicable to any proteomics analysis work-
flow [7]. PFMs are useful to visualize simultaneously
multiple features for the proteins identified in a proteo-
mics analysis. The approach suggests representing pro-
teomic feature sets (including numerical or categorical
features) in gel-resembling synthetic maps, by exploiting
the x and y coordinates, size, color and label attributes
of the spheres.
In previous work [7], we presented a prototype imple-
mentation of PFMs using OpenDX [41], an open source
visualization software package based on IBM’s Visualiza-
tion Data Explorer. OpenDX was the best choice for a
rapid proof of concept of our proposed approach at the
time, due to the simplicity of its modular visualization
environment. The prototype provided a control panel,
which allowed the user to import the features and con-
trol the colors assigned to a feature, as well as basic
interaction capabilities (e.g., zooming, 3D rotation).
However, in order to create a powerful, stand-alone
and user-friendly application for integrative proteomics
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which supports the PFMs concept. Although the under-
lying PFMs approach is the same with the OpenDX-
based implementation, VIP offers a lot more visualiza-
tion options and interaction capabilities with the fea-
tures workspace and the produced visualization, as well
as user control on the graphical encoding. In particular,
in VIP the user can control several parameters of the
visualization through an intuitive interface, such as the
number of sphere sizes to be used, the level of transpar-
ency of the spheres, and the background of the map.
Visual queries can also be performed on the data, in
order to filter the visualization results based on a user-
defined criterion (e.g., proteins with sequence coverage
> 80%). The proteins-spheres that satisfy the given con-
dition get elevated and detached from the map’sl e v e l ,
enabling their easy visual exploration. Additionally, VIP
supports the interaction between the visualization and
the features workspace, allowing the user to explore all
proteomic features that are associated with a protein.
Finally, the interaction between multiple PFMs is sup-
ported allowing the visual comparison of spheres repre-
senting the same proteins across different maps.
Although some of these capabilities were not described
in detail in this paper, they can be easily explored using
the provided data samples after installing the software.
VIP is implemented using the Java platform (Sun JDK
1.6) and released under the GNU General Public
License (GPL). The software has been tested under
Microsoft Windows XP and Vista, Mac OS X and
GNU/Linux.
The backend of VIP, which is responsible for integrat-
ing proteomic features, is based on POML (Proteomics
Object Markup Language), our proposed markup lan-
guage [18]. In particular, we used the Java API for XML
Processing (JAXP), an open source API for efficient
XML validation and parsing [42].
The PFMs visualization in VIP is based on the Java 3D
A P I[ 4 3 ] .J a v a3 Di sap o w e r f u lv i s u a l i z a t i o nc h o i c e
because it offers the advantage of fast application devel-
opment. In particular, it incorporates a high-level scene-
graph model and allows developers to focus on the
objects and the scene composition. Importantly, Java 3D
takes advantage of the graphics hardware in a system,
since it runs on top of either OpenGL or Direct3D tech-
nologies. Thus, it achieves high performance by exploit-
ing hardware acceleration and releasing the CPU of the
system from drawing complex 3D scenes.
Availability and requirements
Project name: VIP
Project home page: http://pelopas.uop.gr/~egian/VIP/
index.html
Operating system: Windows
Programming language: Java
Other requirements: JDK 1.7, Java3D 1.5.2
Licence: GNU GPL
Any restrictions to use by non-academics: none.
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